GlassScriptPhysician profile
Sekar Natarajan
NPI 1164594354
$8,387.72
in general payments reported to CMS, 2019-2025
33 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $1,331 · 2021: $157 · 2022: $1,793 · 2023: $1,159 · 2024: $1,469 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,382.48 | 2019-2024 | Jot Dx, Navitor |
| Glaxosmithkline, LLC. | $1,149.54 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $676.37 | 2020-2025 | Tezspire, Airsupra, Breztri |
| Medtronic, INC. | $453.30 | 2022-2025 | Endurant Iis, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $428.73 | 2020-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $419.46 | 2020-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $358.18 | 2022-2025 | Xarelto, Spravato |
| Edwards Lifesciences Corporation | $343.92 | 2019-2023 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.18 | 2019-2025 | Jardiance |
| Pulmonx Corporation | $172.61 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Cardiovascular Systems INC. | $161.27 | 2019 | |
| Lilly USA, LLC | $155.36 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boston Scientific Corporation | $146.12 | 2023 | Watchman |
| Abbvie INC. | $142.46 | 2024 | |
| Allergan, INC. | $140.43 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $128.75 | 2025 | |
| Genentech USA, INC. | $123.57 | 2019 | |
| Biotronik INC. | $118.39 | 2019 | |
| Medtronic Vascular, INC. | $83.85 | 2019 | |
| Phathom Pharmaceuticals, INC. | $74.46 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $66.33 | 2025 | Ibsrela |
| Pfizer INC. | $64.88 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.24 | 2025 | |
| Novo Nordisk INC | $47.56 | 2022-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $35.99 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $34.46 | 2025 | |
| Amgen INC. | $32.96 | 2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $30.00 | 2020 | |
| Mylan Specialty L.P. | $20.64 | 2020 | |
| Philips North America LLC | $18.63 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.83 | 2025 | Opsynvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.58 | 2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $14.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sekar Natarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.